⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Robbins LLP Urges REGN Investors to Contact the Firm Before the September 14, 2026, Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.
globenewswire.com
REGN
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
businesswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
accessnewswire.com
EYPT
REGN
Shareholders of Regeneron Pharmaceuticals, Inc. (REGN): Protect Your Rights Before September 14, 2026 - Contact Levi & Korsinsky
accessnewswire.com
REGN
Pomerantz LLP Updates Shareholders on Legal Action Brought Against Regeneron Pharmaceuticals, Inc. – REGN
accessnewswire.com
REGN
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Regeneron Pharmaceuticals, Inc. to Contact the Firm Today!
accessnewswire.com
REGN
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
globenewswire.com
NTLA
REGN
ALNY
IONS
PFE
Shareholders of Regeneron Pharmaceuticals, Inc. (REGN): Protect Your Rights Before September 14, 2026 - Contact Levi & Korsinsky
accessnewswire.com
REGN
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit
prnewswire.com
REGN
REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline September 14, 2026
accessnewswire.com
REGN